An additive/substractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients

Journal of Clinical Virology

Volumn 36, Issue 1, 2006, Pages 36-42

  Capdepont, Sophie ^a   Aurillac Lavignolle, Valérie ^b   Faure, Muriel ^a   Dupon, Michel ^a   Morlat, Philippe ^a   Ragnaud, Jean Marie ^a   Chêne, Geneviève ^b   Fleury, Hervé ^a   Masquelier, Bernard ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Algorithm; Didanosine; HIV drug resistance; Nucleoside RT Inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ALGORITHM; ARTICLE; CLINICAL TRIAL; CODON; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIVARIATE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; VIRUS ACTIVATION; VIRUS LOAD; VIRUS MUTATION; ANTIBIOTIC RESISTANCE; BLOOD; DRUG EFFECT; GENETICS; MUTATION; RETROSPECTIVE STUDY; TIME; VIROLOGY;

ALGORITHMS; ANTI-HIV AGENTS; DIDANOSINE; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MULTIVARIATE ANALYSIS; MUTATION; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

EID: 33744542137     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2006.01.008     Document Type: Article

References (27)

1. Boyer P.L., Sarafianos S.G., Arnold E., and Hughes S.H. The M184V mutation reduces the selective excision of zidovudine 5′-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1. J Virol 76 (2002) 3248-3256
2. Brun-Vezinet F., Costagliola D., Khaled M.A., Calvez V., Clavel F., Clotet B., et al. Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther 9 (2004) 465-478
3. Brun-Vezinet F., Descamps D., Ruffault A., Masquelier B., Calvez V., Peytavin G., et al. Clinically relevant interpretation of genotype for resistance to abacavir. AIDS 17 (2003) 1795-1802
4. Costagliola D. Presence of thymidine-associated mutations and response to d4T, abacavir and ddI in the control arm of the Narval ANRS 088 trial. In: 8th Conference on retroviruses and opportunistic infections; 2001.
5. Diallo K., Marchand B., Wei X., Cellai L., Gotte M., and Wainberg M.A. Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity. J Virol 77 (2003) 8621-8632
6. Gao Q., Gu Z., Parniak M.A., Cameron J., Cammack N., Boucher C., et al. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 37 (1993) 1390-1392
7. Gao Q., Gu Z.X., Parniak M.A., Li X.G., and Wainberg M.A. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine. J Virol 66 (1992) 12-19
8. Hirsch M.S., Brun-Vezinet F., Clotet B., Conway B., Kuritzkes D.R., D'Aquila R.T., et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 37 (2003) 113-128
9. Iversen A.K., Shafer R.W., Wehrly K., Winters M.A., Mullins J.I., Chesebro B., et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 70 (1996) 1086-1090
10. Izopet J., Bicart-See A., Pasquier C., Sandres K., Bonnet E., Marchou B., et al. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine. J Med Virol 59 (1999) 507-511
11. Larder B.A., Bloor S., Kemp S.D., Hertogs K., Desmet R.L., Miller V., et al. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother 43 (1999) 1961-1967
12. Larder B.A., and Kemp S.D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246 (1989) 1155-1158
13. Marcelin A.G., Flandre P., Pavie J., Schmidely N., Wirden M., Lada O., et al. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob Agents Chemother 49 (2005) 1739-1744
14. Masquelier B., Race E., Tamalet C., Descamps D., Izopet J., Buffet-Janvresse C., et al. Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors. Antimicrob Agents Chemother 45 (2001) 1836-1842
15. Masquelier B., Tamalet C., Montes B., Descamps D., Peytavin G., Bocket L., et al. Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. Antivir Ther 9 (2004) 315-323
16. Merel P., Pellegrin I., Garrigue I., Caumont A., Schrive M.H., Birac V., et al. Comparison of capillary electrophoresis sequencing with the new CEQ 2000 DNA Analysis System to conventional gel based systems for HIV drug resistance analysis. J Virol Methods 98 (2001) 9-16
17. Miller M.D., Margot N., Lu B., Zhong L., Chen S.S., Cheng A., et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 189 (2004) 837-846
18. Parikh U, Koontz D, Sluis-Cremer N, Hammond J, Bacheler L, Schinazi R, et al. K65R: a multinucleoside resistance mutation of increasing prevalence exhibits bi-directional phenotypic antagonism with TAM. In: 11th Conference on retroviruses and opportunistic infections; 2004 [Abstract 54].
19. Pellegrin I., Izopet J., Reynes J., Denayrolles M., Montes B., Pellegrin J.L., et al. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naïve patients receiving stavudine plus didanosine combination therapy. STADI Group. AIDS 13 (1999) 1705-1709
20. Shirasaka T., Kavlick M.F., Ueno T., Gao W.Y., Kojima E., Alcaide M.L., et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 92 (1995) 2398-2402
21. Sproat M., Pozniak A.L., Peeters M., Winters B., Hoetelmans R., Graham N.M., et al. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine. Antivir Ther 10 (2005) 357-361
22. St Clair M.H., Martin J.L., Tudor-Williams G., Bach M.C., Vavro C.L., King D.M., et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253 (1991) 1557-1559
23. Van Vaerenbergh K., Van Laethem K., Albert J., Boucher C.A., Clotet B., Floridia M., et al. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother 44 (2000) 2109-2117
24. Whitcomb J.M., Parkin N.T., Chappey C., Hellmann N.S., and Petropoulos C.J. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 188 (2003) 992-1000
25. Winters M.A., Bosch R.J., Albrecht M.A., and Katzenstein D.A. Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients. J Infect Dis 188 (2003) 537-540
26. Winters M.A., Coolley K.L., Girard Y.A., Levee D.J., Hamdan H., Shafer R.W., et al. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 102 (1998) 1769-1775
27. Zhang D., Caliendo A.M., Eron J.J., DeVore K.M., Kaplan J.C., Hirsch M.S., et al. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 38 (1994) 282-287